Anika Therapeutics (ANIK +3%) says that it expects FY12 and Q4 to come in better than...
Tuesday, January 22, 1:43 PM ETAnika Therapeutics (ANIK +3%) says that it expects FY12 and Q4 to come in better than expections. Q4 revenue should come in around $22M - $23M, above the current consensus estimate of $20.6M. For FY12, it expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share. Additionally it's appointed Sylvia Cheung as its new CFO, effective April 1, 2013. Cheung will replace Kevin Quinlan, who is leaving effective March 31, 2013.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles